HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating for Fate Therapeutics, maintaining a $5 price target.
August 22, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating for Fate Therapeutics, maintaining a $5 price target. This suggests that the analyst does not expect significant short-term price movement.
The reiteration of a Neutral rating and maintenance of a $5 price target by HC Wainwright & Co. indicates that the analyst does not foresee significant short-term price movement for Fate Therapeutics. This suggests a stable outlook without major catalysts for upward or downward movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100